Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Coutinho
Rita
R
Costa
Dolors
D
Carrió
Ana
A
Muñoz
Concha
C
Vidal
Ana
A
Belkaid
Mohammed
M
Campo
Elias
E
Nomdedeu
Benet
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002986:Clinical Trials as Topic; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014314:Trisomy
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide